Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose: To determine the frequency and prognostic association of molecular markers by anatomic tumor site in patients with stage III colon carcinomas. Experimental Design: In a randomized trial of adjuvant FOLFOX ± cetuximab, BRAFV600E and KRAS (exon 2) mutations and DNA mismatch repair (MMR) proteins were analyzed in tumors (N = 3,018) in relationship to tumor location, including subsite. Cox models were used to assess clinical outcome, including overall survival (OS). Results: KRAS codon 12 mutations were most frequent at the splenic flexure and cecum; codon 13 mutations were evenly distributed. BRAF mutation frequency sharply increased from transverse colon to cecum in parallel with deficient (d) MMR. Nonmutated BRAF and KRAS tumors progressively decreased from sigmoid to transverse (all P < 0.0001). Significantly, poorer OS was found for mutant KRAS in distal [HR, 1.98; 95% confidence interval (CI), 1.49–2.63; P < 0.0001] versus proximal (1.25; 95% CI, 0.97–1.60; P = 0.079) cancers. BRAF status and outcome were not significantly associated with tumor site. Proximal versus distal dMMR tumors had significantly better outcome. An interaction test was significant for tumor site by KRAS (Padjusted = 0.043) and MMR (Padjusted = 0.010) for OS. Significant prognostic differences for biomarkers by tumor site were maintained in the FOLFOX arm. Tumor site was independently prognostic with a stepwise improvement from cecum to sigmoid (OS: Padjusted = 0.001). Conclusions: Mutation in BRAF or KRAS codon 12 was enriched in proximal cancers whereas nonmutated BRAF/KRAS was increased in distal tumors. Significant differences in outcome for KRAS mutations and dMMR were found by tumor site, indicating that their interpretation should occur in the context of tumor location. Clin Cancer Res; 21(23); 5294–304. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 2×
“CIN tumors are enriched in KRAS mutations that occur as early events during tumorigenesis (3).”
Is There a Difference in Survival between Right- versus Left-Sided Colon Cancers?
Meguid, R. A., Slidell, M. B., Wolfgang, C. L., Chang, D. C., & Ahuja, N. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0015-y · Cited by 546
Mouradov, D., Sloggett, C., Jorissen, R. N., Love, C. G., Li, S., Burgess, A. W., Arango, D., Strausberg, R. L., Buchanan, D., Wormald, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0013 · Cited by 375
Identification of a Poor-Prognosis BRAF-Mutant–Like Population of Patients With Colon Cancer
Popovici, V., Budinska, E., Tejpar, S., Weinrich, S., Estrella, H., Hodgson, G., Van Cutsem, E., Xie, T., Bosman, F. T., Roth, A. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5814 · Cited by 236
Deciphering the tête-à-tête between the microbiota and the immune system
Surana, N. K., & Kasper, D. L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72332 · Cited by 120 · cited 1×
“In addition, differences in colonic microbiota have been found in the proximal and distal regions of the colon that may influence molecular events and host immune responses during carcinogenesis in a site-specific manner (28, 29).”
Blons, H., Emile, J. F., Le Malicot, K., Julié, C., Zaanan, A., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J. L., Thaler, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu464 · Cited by 108 · cited 1×
“KRAS codon 13 mutations were of borderline significance for poorer DFS in the PETACC-8 adjuvant study that had identical treatment arms to our trial, yet had fewer codon 13 mutated tumors (136 vs 231) (36).”
Cited by
Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3797 · Cited by 709
“Our observations are broadly consistent with previous reports.(5,7-20,24)Active signalingvia theEGFRpathway ismore frequent in patients with left-sided tumors, ostensibly rendering them more responsive to EGFR inhibitor–based therapy.”
BackgroundResultTesta, U., Pelosi, E., & Castelli, G. (2018) · Medical Sciences · doi:10.3390/medsci6020031 · Cited by 374
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
Stintzing, S., Tejpar, S., Gibbs, P., Thiebach, L., & Lenz, H.-J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.016 · Cited by 277
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Taieb, J., Le Malicot, K., Shi, Q., Penault Lorca, F., Bouché, O., Tabernero, J., Mini, E., Goldberg, R. M., Folprecht, G., Luc Van Laethem, J., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw272 · Cited by 273
Self-citation
Metadata
- Authors
- Sinicrope, F. A., Mahoney, M. R., Yoon, H. H., Smyrk, T. C., Thibodeau, S. N., Goldberg, R. M., Nelson, G. D., Sargent, D. J., & Alberts, S. R.
- Venue
- Clinical Cancer Research
- Published
- 2015-11-30
- Volume
- 21
- Issue
- 23
- Pages
- 5294-5304
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2125402320
- Cited by
- 84
- References
- 7
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0527
- The paper
- Sinicrope, F. A., Mahoney, M. R., Yoon, H. H., Smyrk, T. C., Thibodeau, S. N., Goldberg, R. M., Nelson, G. D., Sargent, D. J., & Alberts, S. R. (2015). Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0527
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.